20% subcutaneous immunoglobulin dosed biweekly for primary immunodeficiency

被引：4
|
作者：
Wasserman, Richard L. [1 ]
Stein, Mark R. [2 ]
Younger, M. Elizabeth M. [2 ]
Fatteh, Shahnaz [3 ]
Haddad, Elie [4 ,5 ]
机构：
[1] Allergy Partners North Texas Res, Dallas, TX USA
[2] Allergy Associates Palm Beaches, North Palm Beach, FL USA
[3] Larkin Community Hosp, South Miami, FL USA
[4] Univ Montreal, CHU St Justine, Dept Pediat, Montreal, PQ, Canada
[5] Univ Montreal, CHU St Justine, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2016年 / 117卷 / 01期
关键词：
REPLACEMENT THERAPY; EFFICACY; SAFETY; IGPRO20; DISEASE;
D O I：
10.1016/j.anai.2016.04.023
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [11] Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency
    Niebur, H. B.
    Duff, C. M.
    Shear, G. F.
    Nguyen, D.
    Alberdi, T. K.
    Dorsey, M. J.
    Sleasman, J. W.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 181 (03): : 441 - 450
  • [12] Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review
    Anderson-Smits, Colin
    Park, Michelle
    Bell, Judith
    Mitchell, Sarah
    Hartley, Louise
    Hawe, Emma
    IMMUNOTHERAPY, 2022, 14 (05) : 373 - 387
  • [13] Evaluating Dose Ratio of Subcutaneous to Intravenous Immunoglobulin Therapy Among Patients With Primary Immunodeficiency Disease Switching to 20% Subcutaneous Immunoglobulin Therapy
    Krishnarajah, Girishanthy
    Lehmann, Jee-Yeon K.
    Ellman, Brian
    Bhak, Rachel H.
    DerSarkissian, Maral
    Leader, Deane, Jr.
    Bullinger, Ann L.
    Duh, Mei Sheng
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 (15): : S475 - S481
  • [14] Successful use of 20% subcutaneous immunoglobulin in pregnant women with primary immune deficiency
    Duff, Carla
    Krishnaswamy, Guha
    Ghably, Jack
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 116 (01) : 83 - 85
  • [15] Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases
    Dumas, Todd
    Berry, N. Seth
    Wolfsegger, Martin
    Jolles, Stephen
    McCoy, Barbara
    Yel, Leman
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 71 : 404 - 410
  • [16] Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
    Skoda-Smith, Suzanne
    Torgerson, Troy R.
    Ochs, Hans D.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 1 - 10
  • [17] Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
    Hagan, John B.
    Fasano, Mary B.
    Spector, Sheldon
    Wasserman, Richard L.
    Melamed, Isaac
    Rojavin, Mikhail A.
    Zenker, Othmar
    Orange, Jordan S.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2010, 30 (05) : 734 - 745
  • [18] Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency
    Wasserman, Richard L.
    Melamed, Isaac
    Nelson, Robert P., Jr.
    Knutsen, Alan P.
    Fasano, Mary Beth
    Stein, Mark R.
    Rojavin, Mikhail A.
    Church, Joseph A.
    CLINICAL PHARMACOKINETICS, 2011, 50 (06) : 405 - 414
  • [19] Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases
    Mach-Tomalska, Monika
    Pituch-Noworolska, Anna
    Bien, Ewa
    Malanowska, Magdalena
    Machura, Edyta
    Pukas-Bochenek, Anna
    Chrobak, Ewelina
    Pac, Malgorzata
    Pietrucha, Barbara
    Drygala, Szymon
    Kamieniak, Marta
    Kasprzak, Jakub
    Heropolitanska-Pliszka, Edyta
    IMMUNOTHERAPY, 2024, 16 (06) : 391 - 403
  • [20] Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases
    Baumann, Ulrich
    Fasshauer, Maria
    Pausch, Christine
    Wittkowski, Helmut
    Hermann, Corinna
    Pittrow, David
    Borte, Michael
    IMMUNOTHERAPY, 2022, 14 (02) : 135 - 143
12345